Liver Fibrosis - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 199
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: L1EE17B4E07EN
Leaflet:

Download PDF Leaflet

Liver Fibrosis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Liver Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Liver Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Fibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Liver Fibrosis
  • The report reviews pipeline therapeutics for Liver Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Liver Fibrosis therapeutics and enlists all their major and minor projects
  • The report assesses Liver Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Liver Fibrosis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Liver Fibrosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Liver Fibrosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Liver Fibrosis Overview
Therapeutics Development
Pipeline Products for Liver Fibrosis - Overview
Pipeline Products for Liver Fibrosis - Comparative Analysis
Liver Fibrosis - Therapeutics under Development by Companies
Liver Fibrosis - Therapeutics under Investigation by Universities/Institutes
Liver Fibrosis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Liver Fibrosis - Products under Development by Companies
Liver Fibrosis - Products under Investigation by Universities/Institutes
Liver Fibrosis - Companies Involved in Therapeutics Development
Advinus Therapeutics Ltd
Akarna Therapeutics Ltd.
Angion Biomedica Corp.
Asubio Pharma Co., Ltd.
aTyr Pharma, Inc.
Beijing Kawin Technology Share-Holding Co., Ltd.
BioLineRx, Ltd.
Bioneer Corporation
BiOrion Technologies B.V.
Bird Rock Bio, Inc.
Bristol-Myers Squibb Company
Cellmid Limited
ContraVir Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Dr. Falk Pharma GmbH
Dynavax Technologies Corporation
Evotec AG
Galectin Therapeutics, Inc.
Genfit SA
Gilead Sciences, Inc.
GNI Group Ltd.
HEC Pharm Co., Ltd.
Immuron Limited
Intercept Pharmaceuticals, Inc.
INVENT Pharmaceuticals, Inc.
Isarna Therapeutics GmbH
KineMed, Inc.
LG Life Science LTD.
Nitto Denko Corporation
Pfizer Inc.
Pharmaxis Limited
Promedior, Inc.
Promethera Biosciences S.A.
ProMetic Life Sciences Inc.
Ribomic Inc.
RXi Pharmaceuticals Corporation
Silence Therapeutics Plc
TCM Biotech International Corp
Vascular Biogenics Ltd.
Virobay Inc.
XTuit Pharmaceuticals, Inc.
Liver Fibrosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ANG-3070 - Drug Profile
ANG-3281 - Drug Profile
Antisense RNAi Oligonucleotide for Liver Disease - Drug Profile
Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide for Liver Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Liver Fibrosis - Drug Profile
Antisense RNAi Oligonucleotide to Inhibit HMGB1 for Liver Fibrosis - Drug Profile
ASB-14780 - Drug Profile
BL-1210 - Drug Profile
BMS-986171 - Drug Profile
BOT-162 - Drug Profile
BOT-191 - Drug Profile
CAB-102 - Drug Profile
CPI-43132 - Drug Profile
CT-140 - Drug Profile
DB-036 - Drug Profile
Drug to Inhibit Galectin-3 for Liver Fibrosis, Respiratory Disorder and Kidney Fibrosis - Drug Profile
Drugs for Tissue Fibrosis - Drug Profile
DV-1079 - Drug Profile
F-351 - Drug Profile
Gene Therapy for Liver Fibrosis - Drug Profile
GMCT-01 - Drug Profile
GRMD-02 - Drug Profile
GS-444217 - Drug Profile
HEC-585 - Drug Profile
HepaStem - Drug Profile
IMM-124E - Drug Profile
INT-767 - Drug Profile
INV-240 - Drug Profile
ISTH-0047 - Drug Profile
KW-0 - Drug Profile
KW-012 - Drug Profile
LC-280126 - Drug Profile
melittin - Drug Profile
Monoclonal Antibodies to Antagonize TGF-Beta Receptor Type-1 for HCV associated Liver Fibrosis - Drug Profile
MOR-8457 - Drug Profile
MRI-1867 - Drug Profile
ND-L02s0201 - Drug Profile
norursodeoxycholic acid - Drug Profile
noscapine - Drug Profile
PBI-4050 - Drug Profile
PRM-151 - Drug Profile
Proteins for Liver Fibrosis - Drug Profile
PXS-4820 - Drug Profile
PXS-5033A - Drug Profile
RBM-006 - Drug Profile
Recombinant MMP-9 Replacement for Liver Fibrosis, Pulmonary Fibrosis, Dupuytren Contracture, Peyronies Disease and Transplantation - Drug Profile
RXI-209 - Drug Profile
RYI-018 - Drug Profile
selonsertib - Drug Profile
selonsertib + simtuzumab - Drug Profile
Small Molecule for Liver Fibrosis - Drug Profile
Small Molecule for Liver Fibrosis - Drug Profile
Small Molecule to Agonize FXR for NASH and Liver Fibrosis - Drug Profile
Small Molecule to Antagonize AlphaVBetaI for Fibrosis - Drug Profile
Small Molecule to Antagonize GPR91 for Retinal Angiogenesis and Liver Fibrosis - Drug Profile
Small Molecules for Hepatic Fibrosis - Drug Profile
Small Molecules for Liver Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
Stem Cell Therapy for Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile
Stem Cell Therapy for Liver Fibrosis and Liver Cirrhosis - Drug Profile
TCM-808FB - Drug Profile
TGFTX-4 - Drug Profile
VB-201 - Drug Profile
VB-703 - Drug Profile
VBY-376 - Drug Profile
VBY-825 - Drug Profile
Liver Fibrosis - Dormant Projects
Liver Fibrosis - Discontinued Products
Liver Fibrosis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 194

LIST OF TABLES

Number of Products under Development for Liver Fibrosis, H2 2016
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Investigation by Universities/Institutes, H2 2016
Liver Fibrosis - Pipeline by Advinus Therapeutics Ltd, H2 2016
Liver Fibrosis - Pipeline by Akarna Therapeutics Ltd., H2 2016
Liver Fibrosis - Pipeline by Angion Biomedica Corp., H2 2016
Liver Fibrosis - Pipeline by Asubio Pharma Co., Ltd., H2 2016
Liver Fibrosis - Pipeline by aTyr Pharma, Inc., H2 2016
Liver Fibrosis - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H2 2016
Liver Fibrosis - Pipeline by BioLineRx, Ltd., H2 2016
Liver Fibrosis - Pipeline by Bioneer Corporation, H2 2016
Liver Fibrosis - Pipeline by BiOrion Technologies B.V., H2 2016
Liver Fibrosis - Pipeline by Bird Rock Bio, Inc., H2 2016
Liver Fibrosis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Liver Fibrosis - Pipeline by Cellmid Limited, H2 2016
Liver Fibrosis - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016
Liver Fibrosis - Pipeline by Dicerna Pharmaceuticals, Inc., H2 2016
Liver Fibrosis - Pipeline by Digna Biotech, S.L., H2 2016
Liver Fibrosis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
Liver Fibrosis - Pipeline by Dynavax Technologies Corporation, H2 2016
Liver Fibrosis - Pipeline by Evotec AG, H2 2016
Liver Fibrosis - Pipeline by Galectin Therapeutics, Inc., H2 2016
Liver Fibrosis - Pipeline by Genfit SA, H2 2016
Liver Fibrosis - Pipeline by Gilead Sciences, Inc., H2 2016
Liver Fibrosis - Pipeline by GNI Group Ltd., H2 2016
Liver Fibrosis - Pipeline by HEC Pharm Co., Ltd., H2 2016
Liver Fibrosis - Pipeline by Immuron Limited, H2 2016
Liver Fibrosis - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016
Liver Fibrosis - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
Liver Fibrosis - Pipeline by Isarna Therapeutics GmbH, H2 2016
Liver Fibrosis - Pipeline by KineMed, Inc., H2 2016
Liver Fibrosis - Pipeline by LG Life Science LTD., H2 2016
Liver Fibrosis - Pipeline by Nitto Denko Corporation, H2 2016
Liver Fibrosis - Pipeline by Pfizer Inc., H2 2016
Liver Fibrosis - Pipeline by Pharmaxis Limited, H2 2016
Liver Fibrosis - Pipeline by Promedior, Inc., H2 2016
Liver Fibrosis - Pipeline by Promethera Biosciences S.A., H2 2016
Liver Fibrosis - Pipeline by ProMetic Life Sciences Inc., H2 2016
Liver Fibrosis - Pipeline by Ribomic Inc., H2 2016
Liver Fibrosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2016
Liver Fibrosis - Pipeline by Silence Therapeutics Plc, H2 2016
Liver Fibrosis - Pipeline by TCM Biotech International Corp, H2 2016
Liver Fibrosis - Pipeline by Vascular Biogenics Ltd., H2 2016
Liver Fibrosis - Pipeline by Virobay Inc., H2 2016
Liver Fibrosis - Pipeline by XTuit Pharmaceuticals, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Liver Fibrosis - Dormant Projects, H2 2016
Liver Fibrosis - Dormant Projects (Contd..1), H2 2016
Liver Fibrosis - Dormant Projects (Contd..2), H2 2016
Liver Fibrosis - Dormant Projects (Contd..3), H2 2016
Liver Fibrosis - Discontinued Products, H2 2016 188

LIST OF FIGURES

Number of Products under Development for Liver Fibrosis, H2 2016
Number of Products under Development for Liver Fibrosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 377 pages
Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 260 pages
Cystic Fibrosis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 389 pages

Ask Your Question

Liver Fibrosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: